Using CRISPR, a gene editing technology, Babcock will trace how a single cell evolves into leukemia and identify potential therapeutic targets for patients with B-ALL. The award will allow Babcock, a third-year student of the Cancer Biology Graduate Program at Emory’s Laney Graduate School, to identify the cell of origin for B-cell acute lymphoblastic leukemia (B-ALL) in infants and children.ī-ALL is the most common childhood cancer, but its specific origins remain largely unknown. They will each receive an annual $40,000 stipend for a two-year period to fund their research and to share their findings with the field at the ASH Annual Meeting and Exposition. and Canadian-based applicants will conduct hematology research in one of the following categories: basic, translational, outcomes-based or patient-oriented clinical research. This award aims to encourage graduate students in the United States and Canada to pursue a career in academic hematology.įrom July 1, 2022, to June 30, 2024, AGHA participants selected from a competitive pool of U.S.
Emory University student Ben Babcock has been selected by the American Society of Hematology (ASH) to participate as one of seven graduate students in the 2022 ASH Graduate Hematology Award (AGHA).
